LONGITUDINAL CAPACITY REPORT
L. WHITFIELD · MRN 40615-CGenerated Jul 16, 2026 · UnDun Health
PATIENT CAPACITY REVIEW
Lena Whitfield
46 yrs · Female · HRT · Reporting period Apr–Jul 2026 (12 weeks)
Patient view ↗
COMPOSITE · vs BASELINE
+1.3%
▲ Improving · watch
UNDUN INTELLIGENCE · SUMMARY
Composite is +1.3%, with vitality +3.0% and easing symptoms six weeks into HRT, but nighttime resting heart rate is up +5 bpm and HRV is down −8%. Both are below threshold for now and warrant watching rather than a change today.
FLAGGED THIS CYCLE
No single domain past the meaningful-change threshold.
RECOMMENDED ACTION
Message the patient; check blood pressure and consider a transdermal route over oral; reassess dose at the next visit.
Concise view. Switch to Standard for domains and trajectory, or Comprehensive for the full workup: heat map, aging projection, intervention impact and labs.
Capacity by domain
| DOMAIN | vs BASELINE | 12-WK TREND | STATUS |
|---|---|---|---|
| Vitality | +3.0% | improving | STABLE |
| Psychological | +2.2% | improving | STABLE |
| Cognitive | +0.8% | holding | STABLE |
| Locomotion | +0.4% | holding | STABLE |
| Sensory | 0.0% | stable | STABLE |
Composite is the mean of the five domain scores, each expressed as percent from personal baseline.
Composite trajectory
Composite capacity, percent from personal baseline. Symptom-driven gains since initiation; cardiovascular signals worth watching.
INTERVENTION TIMELINE
HRT
Suggested care plan
MONITOR
UNDUN INTELLIGENCE · DECISION SUPPORT
Objective: Maintain symptom relief while watching the emerging cardiovascular signals.
MONITORING
Check blood pressure in clinic and review home readings.
MEDICATION
Consider a transdermal route over oral given the cardiovascular signal.
MEDICATION
Reassess dose at the next visit.
MONITORING
Monitor nighttime resting heart rate and HRV weekly.
FOLLOW-UP
Re-evaluate in 4 weeks; escalate if either crosses threshold.
Draft plan generated by UnDun Intelligence. Requires clinician review and sign-off before it takes effect.
Signed Date
Wearable vitals
Resting heart rate (night)+5 bpm
HRV (rMSSD)−8%
Night awakeningseasing
Sleep duration6.9 h
Data coverage94%
Active interventions
HRT (oral)WEEK 6
Adherence 97%. Symptom relief good; watch cardiovascular signals.
Sleep hygiene planACTIVE
Awakenings decreasing; reinforce consistency.
Week-by-week detail
W1
W2
W3
W4
Composite
+0.6
+0.9
+1.1
+1.3
Vitality
+1.4
+2.2
+2.6
+3.0
Psychological
+1.0
+1.6
+1.9
+2.2
Cognitive
+0.4
+0.6
+0.7
+0.8
Locomotion
+0.2
+0.3
+0.3
+0.4
Sensory
0.0
0.0
0.0
0.0
Each domain by week, percent from baseline. Composite is the row mean.
Sleep & recovery
Avg sleep duration6.9 h
Near target
Sleep consistency80%
Good
Night awakeningsEasing
Improving
Deep sleep1.2 h
17% of night
Resting HR (night)+5 bpm
Up — watch
HRV (rMSSD)−8%
Dipping
Body composition & activity
Weight−1.0%
Stable
Lean mass+0.6%
Holding
Body fat−0.8%
Down
Avg daily steps7,100
Good
Zone 2 minutes120 / wk
Near target
Active days21 / 30
Consistent
Measured intervention effect
Composite capacity in the four weeks before versus after each intervention started, isolating its measured effect.
| INTERVENTION | 4-WK PRE | 4-WK POST | Δ |
|---|---|---|---|
| HRT (oral) | +0.2% | +1.3% | +1.1% |
Projected intervention impact
Estimated effect of each lever at target adherence, with the projected years of function preserved. Illustrative, model-based projections.
VITALITY · HORMONAL
+6%
above baseline
3 yrs
delayed symptoms
HRT (transdermal)
Symptom relief+4%
Transdermal route+2%
PSYCHOLOGICAL · SLEEP
+3%
above baseline
2 yrs
delayed symptoms
Sleep hygiene
Fewer awakenings+2%
Consistency+1%
Domain heat map
On track
Watch
Concerning
Vitality
Psychological
Cognitive
Locomotion
Sensory
12 wk agonow
Weekly capacity status by domain, relative to personal baseline. Amber marks drift; red marks a crossed threshold.
Aging trajectory projection
YOUR TRAJECTORY
REFERENCE AGING
SYMPTOM THRESHOLD
Trajectory stays comfortably above threshold past age 86 provided cardiovascular signals stay sub-threshold.
Recent labs & biomarkers
| MARKER | VALUE | REF RANGE | FLAG |
|---|---|---|---|
| Estradiol | 92 pg/mL | therapeutic | — |
| hs-CRP | 1.1 mg/L | <1.0 | HIGH |
| Blood pressure | 128/82 | <130/80 | — |
| ApoB | 76 mg/dL | <90 | — |
| Ferritin | 45 ng/mL | 15–150 | — |
| TSH | 2.1 mIU/L | 0.4–4.0 | — |
Most recent panel on file. Flags are relative to standard reference ranges, not personalized targets.
Reviewing clinician: Dr. A. Okafor · UnDun Health. This report summarizes passively collected wearable and body-composition data interpreted against the patient's own baseline. UnDun Intelligence findings are decision-support hypotheses, not diagnoses, and do not replace clinical judgment.